Welcome to the Homepage of the GLIOMARK project!
The objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer Tomography (SPECT).
The outcome of GLIOMARK is a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT.
Gliomas are recognized as a rare tumor disease with poor prognosis. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. Our kit employs TTF/SPECT and enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies.